Early treatment is effective against HIV

WASHINGTON: Early antiviral treatment after diagnosis of HIV infection significantly reduces the likelihood of getting AIDS or other serious illnesses, according to results from a large international clinical trial published on Wednesday.
The study was presented a year earlier than planned after preliminary data showed that people who received treatment from diagnosis were 53 per cent less likely to die or develop a serious illness such as AIDS compared to a control group where treatment began later when the immune system is weakened.
Researchers said this data combined with previous studies showing that antiviral drugs help prevent HIV transmission to healthy sexual partners indicate that such treatment is beneficial for everyone diagnosed with the virus.
The study began in 2011 in 35 countries with 4,684 HIV-infected men and women over the age of 18.
An estimated 35 million people are infected with HIV worldwide, while only 13 million people get treatment, according to the latest figures.
The US Centers for Disease Control and Prevention already recommends starting antiviral after HIV diagnosis. -AFP

Must Read: What is Female Viagra...?

Comments

You Will Never Thought That Knowing What Is Health Insurance Could Be So Beneficial!

some useful vegetable for Breast Cancer prevention

Broccoli C auliflower Brussel Sprouts Spinach Coliards Tomatoes Kale Cabbage Carrots Have more sex.....Prevention Cancer

FDA Panel Votes to Approve 'Female Viagra' With Conditions After Third Hearing

By GILLIAN MOHNEY and LANA ZAK via Good Morning America An expert panel for the U.S. Food and Drug Administration voted today to approve a drug that has been dubbed the "female Viagra" after two previous attempts failed to gain approval. The FDA is set to make a final decision in August, and while the agency generally follows to the panelists' vote, it is not bound to adhere to it. Medical experts from the FDA examined the evidence on the effectiveness of the drug flibanserin, designed to help per-menopausal women with Hypo active Sexual Desire Disorder (HSDD). This is the third time the drug has been presented to the FDA, after previous attempts to get the drug approved failed in part due to the agency having concerns about whether its benefits outweighed the risks. A mother and her daughter were among those to offer emotional testimony to the FDA panel today. The mother, Barbara, talked about how her relationships with her husband and family became st

Healthy Minds

Search This Blog